Clinical Trial Update: Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer

View source ↗

Summary

A registry update for a real-world study of first-line tislelizumab in advanced non-small cell lung cancer, evaluating treatment strategies and survival outcome…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Non-Small-Cell Lung Cancer, Non-Small-Cell Lung Cancer Stage IV | Status: ENROLLING_BY_INVITATION